11.30 am – Practice-changing treatments – N. Russel
11.45 am – Emerging molecularly-targeted therapeutics – G. Martinelli
12.00 pm – Novel approaches to targeted epigenetic therapy – S. Sica
12.15 pm – Clinical use of MRD testing – A. Venditti
12.30 pm – Recent developments in immunotherapy – A. Isidori
12.45 pm – Discussion

01.00 pm – Break

01.45 pm – Relevance of molecular characterization in prognostic stratification and choice of therapy – M.G. Della Porta
02.00 pm – Targeted therapy in low risk MDS – U. Platzbecker
02.15 pm – Novel therapies in high risk MDS – M.T. Voso
02.30 pm – Relevance of quality of life and patient reported outcome in designing therapeutic strategies in MDS – E.N. Oliva
02.45 pm – Transplant options in 2020 – E. Angelucci
03.00 pm – Discussion

03.15 pm – The stem cell of MPN – R.C. Skoda
03.30 pm – Balancing toxicity and efficacy of JAK2 inhibitors – F. Passamonti
03.45 pm – Managing loss of response to ruxolitinib – P. Guglielmelli
04.00 pm – Unusual thrombosis – S. Siragusa
04.15 pm – Mutations and target treatment in systemic mastocytosis – F. Mannelli
04.30 pm – Discussion

04.45 pm – Break

05.00 pm – JOHN GOLDMAN LECTURE – M. Baccarani
Introduced by A.M. Carella

10.15 am – Prognostic/predictive factors in the target treatment era – F. Bosch
10.30 am – The standard of care in CLL: new guidelines – P. Ghia
10.45 am – Treatment with novel drugs: until progression?
• Yes – F.R. Mauro
• No – M. Montillo
11.15 am – Discussion